Hydrogen’s impact on lung injury in mice: Nrf2/HO-1/HMGB1 pathwayScientific Research


original title: Effects of hydrogen on lung injury in wild-type and Nrf2 gene knockout mice: relationship with Nrf2/HO-1/HMGB1 pathway

Authors:

Man Yang, Yang Yu, Keliang Xie, Yong Yu

DOI: 10.3760/cma.j.issn.2095-4352.2019.07.013

-

Abstract:

Objective: To investigate the key role of nuclear factor E2-related factor 2 (Nrf2) in the treatment of lung injury in sepsis mice by regulating Nrf2/heme oxygenase-1 (HO-1)/high mobility group protein B1 (HMGB1) pathway.

Methods: 120 male wild type (WT) and 120 Nrf2 knockout (Nrf2-KO) ICR mice were randomly divided into Sham group, H2 control group (Sham+H2 group), cecal ligation and puncture (CLP) induced sepsis model group (CLP group) and H2 intervention group (CLP+H2 group), with 30 mice in each group. The sepsis model was reproduced by CLP. The same operation was done in Sham group and Sham+H2 group except CLP. The mice in Sham+H2 group and CLP+H2 group were challenged by 2% H2 for 1 hour at 1 hour and 6 hours after operation respectively, while the mice in Sham group and CLP group only inhaled air. Twenty mice in each group were collected to observe the 7-day survival. The other mice were sacrificed at 24 hours after the reproduction of model, and the lung tissues were harvested. The activities of superoxide dismutase (SOD) and catalase (CAT) and malondialdehyde (MDA) contents were determined by enzyme-linked immunosorbent assay (ELISA). The expressions of HO-1 and HMGB1 were determined by Western Blot, and the positive expression of HO-1 was also detected by immunofluorescence.

Results: Compared with Sham groups, the 7-day survival rates of WT and Nrf2-KO mice in CLP groups were significantly lowered [WT: 0% (0/20) vs. 100% (20/20), Nrf2-KO: 0% (0/20) vs. 100% (0/20), both P < 0.05]; the 7-day survival rates of CLP+H2 group in WT mice were significantly higher than those of CLP group [40% (8/20) vs. 0% (0/20), P < 0.05], but there was no significant difference between CLP+H2 group and CLP group in Nrf2-KO mice [0% (0/20) vs. 0% (0/200), P > 0.05]. In WT mice, compared with Sham group, the activities of SOD and CAT in lung tissue of CLP group were decreased significantly [SOD (kU/g): 131.30±28.21 vs. 251.00±22.84, CAT (kU/g): 13.43±1.52 vs. 20.76±1.63, both P < 0.01], the MDA content, the expressions of HO-1 and HMGB1 were increased significantly [MDA (μmol/g): 6.26±1.18 vs. 4.16±0.58, HO-1/β-actin: 0.160±0.045 vs. 0.023±0.005, HMGB1/β-actin: 0.656±0.055 vs. 0.005±0.001, all P < 0.05]. Compared with CLP group, the activities of SOD, CAT and HO-1 expression in lung tissue of CLP+H2 group were significantly increased [SOD (kU/g): 220.32±35.06 vs. 131.30±28.21, CAT (kU/g): 18.95±2.49 vs. 13.43±1.52, HO-1/β-actin: 0.376±0.025 vs. 0.160±0.045, all P < 0.01], while the MDA contents and HMGB1 expressions were significantly decreased [MDA (μmol/g): 4.26±0.75 vs. 6.26±1.18, HMGB1/β-actin: 0.343±0.040 vs. 0.656±0.055, both P < 0.05]. In Nrf2-KO mice, compared with Sham group, the activity of CAT in CLP group was significantly lowered (kU/g: 12.28±1.49 vs. 19.11±1.53, P < 0.01), MDA contents and the expressions of HO-1 and HMGB1 were significantly increased [MDA (μmol/g): 6.85±0.54 vs. 4.59±0.50, HO-1/β-actin: 0.063±0.005 vs. 0.021±0.003, HMGB1/β-actin: 0.713±0.035 vs. 0.005±0.001, all P < 0.01], while there was no significant difference in SOD activity (kU/g: 114.19±9.94 vs. 135.75±28.10, P > 0.05). There was no significant difference in above parameters between CLP+H2 group and CLP group. Conclusions: H2 inhibits lung injury in septic mice through Nrf2/HO-1/HMGB1 pathway. Nrf2 plays a major role in the treatment of septic lung injury by H2.

Hydrogen Therapy At Home

Beyond clinical settings, hydrogen therapy is successfully used at home — thanks to our internationally recognised devices.

At “Hydrogen Technologies” Ltd., for more than 15 years we have been developing and manufacturing “HHO Bulgaria” devices for health with hydrogen.

We are among the pioneers in the field and, unlike many of our competitors worldwide, we continue to exist and to innovate!

By choosing “HHO Bulgaria”, you support both your own health and Bulgarian innovation and manufacturing.

Meet HBS10 — Europe’s best-selling hydrogen therapy device, both in Bulgaria and worldwide.

HBS10 — Hydrogen therapy device

HBS10 → More about HBS10 TOP PRODUCT

Inhalation and water

H2 therapy device
2-in-1

Output

Hydrogen inhalation
450 ml
HHO gas per minute

Concentration

Hydrogen water
-250 mV
ORP

The device is a 2-in-1 system: use it for hydrogen inhalation or to prepare hydrogen-rich water (“hydrogen water”).

HBS10 is the only European hydrogen therapy device chromatographically tested for safety at the Bulgarian Academy of Sciences (BAS)!

In addition, the device is:

  • CE certified;
  • Tested and recommended by the renowned hydrogen therapy platform H2HUBB, USA.

Order online

H2BOOSTR Mini is our newest alternative for hydrogen therapy at home.

H2BOOSTR Mini — hydrogen water system with 100% pure molecular hydrogen

H2BOOSTR Mini → More about H2BOOSTR NEW

100% pure molecular hydrogen

100%
pure molecular
hydrogen

Ready in 30 seconds

30 seconds
to prepare

High hydrogen concentration

3.2–3.6 mg
hydrogen
per litre of water

The system saturates water with 100% pure molecular hydrogen (“hydrogen water” with maximum dissolved hydrogen).

H2BOOSTR Mini reflects Bulgarian innovation: the technology is fully engineered in Bulgaria and is the world’s only solution that prepares one litre of hydrogen water in just 30 seconds with over 3 ppm of 100% pure molecular hydrogen!

Order online

FREE PERSONAL
CONSULTATION

  • SHORT AND
    STRAIGHT TO THE POINT
  • SPECIFIC
    TO YOUR NEEDS
  • CLEAR, AND IN
    EASY-TO-UNDERSTAND LANGUAGE

Discover How Molecular Hydrogen Therapy
can help You
and Your Loved Ones.

Ask The World's First Specialized H2 Consultant,
equipped with knowledge acquired from:

2500+

Clinical Studies,
Scientific Reports and Publications
conducted Worldwide

Analyses, consultations and summaries, prepared and published on our websites by Medical Specialists:

  • Dr. Ivan Vlasov
  • Dr. Victoria Kaludova
Sylvia Panayotova - H2 Consultant

Trained by:

Sylvia
Panayotova

Hydrogen Therapy Consultant,
certified by the Molecular Hydrogen
Institute (MHI) in the U.S.